TherapeuticsMD (TXMD) Competitors $1.04 +0.01 (+0.97%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$1.04 +0.00 (+0.48%) As of 04/15/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TXMD vs. RPTX, SKYE, CUE, ITRM, ATNM, MRSN, XFOR, DYAI, OTLK, and CTMXShould you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include Repare Therapeutics (RPTX), Skye Bioscience (SKYE), Cue Biopharma (CUE), Iterum Therapeutics (ITRM), Actinium Pharmaceuticals (ATNM), Mersana Therapeutics (MRSN), X4 Pharmaceuticals (XFOR), Dyadic International (DYAI), Outlook Therapeutics (OTLK), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry. TherapeuticsMD vs. Repare Therapeutics Skye Bioscience Cue Biopharma Iterum Therapeutics Actinium Pharmaceuticals Mersana Therapeutics X4 Pharmaceuticals Dyadic International Outlook Therapeutics CytomX Therapeutics Repare Therapeutics (NASDAQ:RPTX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership. Does the media favor RPTX or TXMD? In the previous week, TherapeuticsMD had 2 more articles in the media than Repare Therapeutics. MarketBeat recorded 5 mentions for TherapeuticsMD and 3 mentions for Repare Therapeutics. Repare Therapeutics' average media sentiment score of 0.96 beat TherapeuticsMD's score of 0.91 indicating that Repare Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repare Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TherapeuticsMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, RPTX or TXMD? Repare Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Do analysts prefer RPTX or TXMD? Repare Therapeutics currently has a consensus target price of $4.50, suggesting a potential upside of 309.09%. Given Repare Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Repare Therapeutics is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50TherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, RPTX or TXMD? TherapeuticsMD has lower revenue, but higher earnings than Repare Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepare Therapeutics$53.48M0.87-$93.80M-$2.00-0.55TherapeuticsMD$1.76M6.84-$10.28MN/AN/A Does the MarketBeat Community favor RPTX or TXMD? TherapeuticsMD received 343 more outperform votes than Repare Therapeutics when rated by MarketBeat users. However, 64.18% of users gave Repare Therapeutics an outperform vote while only 58.40% of users gave TherapeuticsMD an outperform vote. CompanyUnderperformOutperformRepare TherapeuticsOutperform Votes4364.18% Underperform Votes2435.82% TherapeuticsMDOutperform Votes38658.40% Underperform Votes27541.60% Is RPTX or TXMD more profitable? Repare Therapeutics has a net margin of -99.76% compared to TherapeuticsMD's net margin of -207.77%. TherapeuticsMD's return on equity of -14.08% beat Repare Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Repare Therapeutics-99.76% -40.87% -35.07% TherapeuticsMD -207.77%-14.08%-9.61% Do institutionals and insiders hold more shares of RPTX or TXMD? 85.1% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 21.6% of Repare Therapeutics shares are owned by insiders. Comparatively, 2.3% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryRepare Therapeutics beats TherapeuticsMD on 9 of the 16 factors compared between the two stocks. Remove Ads Get TherapeuticsMD News Delivered to You Automatically Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXMD vs. The Competition Export to ExcelMetricTherapeuticsMDPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.04M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E RatioN/A6.7921.7317.82Price / Sales6.84225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book0.385.866.464.00Net Income-$10.28M$141.86M$3.20B$247.23M7 Day Performance16.85%4.50%2.86%1.45%1 Month Performance43.41%-12.65%-8.55%-6.24%1 Year Performance-45.26%-11.06%10.47%0.60% TherapeuticsMD Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXMDTherapeuticsMD1.1878 of 5 stars$1.04+1.0%N/A-46.7%$12.04M$1.76M0.00420RPTXRepare Therapeutics3.3852 of 5 stars$0.96-4.0%$4.50+368.9%-68.3%$40.80M$53.48M-0.48180Short Interest ↓News CoverageSKYESkye Bioscience1.0201 of 5 stars$1.39-49.3%$18.00+1,199.6%-86.8%$40.27MN/A-1.8211News CoverageGap UpCUECue Biopharma4.3333 of 5 stars$0.63-7.3%$4.75+659.0%-49.8%$39.64M$9.53M-0.7060News CoverageGap UpITRMIterum Therapeutics1.8245 of 5 stars$1.11-1.8%$5.00+350.5%-27.3%$38.39MN/A-0.8510Gap DownATNMActinium Pharmaceuticals2.001 of 5 stars$1.22-5.4%$7.40+506.6%N/A$38.06M$81,000.00-0.8830MRSNMersana Therapeutics4.0131 of 5 stars$0.31+0.8%$4.00+1,210.2%-90.8%$38.05M$40.50M-0.50150Positive NewsGap UpXFORX4 Pharmaceuticals4.5886 of 5 stars$0.21-1.2%$2.83+1,235.8%-83.4%$36.83M$2.56M-2.3680Positive NewsDYAIDyadic International1.9702 of 5 stars$1.22-2.4%$6.00+391.8%-26.3%$36.71M$3.50M-5.307Short Interest ↑Positive NewsGap DownOTLKOutlook Therapeutics1.7327 of 5 stars$1.14-5.0%$10.20+794.7%-83.9%$36.50MN/A-0.1520Gap DownCTMXCytomX Therapeutics4.052 of 5 stars$0.43-5.3%$5.02+1,064.0%-67.9%$36.49M$138.10M2.54170Analyst ForecastNews CoverageGap Up Remove Ads Related Companies and Tools Related Companies Repare Therapeutics Alternatives Skye Bioscience Alternatives Cue Biopharma Alternatives Iterum Therapeutics Alternatives Actinium Pharmaceuticals Alternatives Mersana Therapeutics Alternatives X4 Pharmaceuticals Alternatives Dyadic International Alternatives Outlook Therapeutics Alternatives CytomX Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TXMD) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TXMD Stock Free TXMD Stock Alerts